Brought to you by 
Mersana raises $27mm through Series A-1 round
02 Aug 2012
Executive Summary
Mersana Therapeutics Inc. (polymer-based drug delivery technology for cancer treatments) raised $27mm through its Series A-1 recapitalization financing round. New investors New Enterprise Associates (lead) and Pfizer Venture Investments were joined by returning backers Fidelity Biosciences, ProQuest Investments, Rho Ventures, and Harris & Harris Group. New Enterprise Associates' general partner David Mott will become chairman of Mersana, joined on the company's board by NEA principal Sara Nayeem, MD.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mersana raises $27mm through Series A-1 round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice